In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endoceutics Inc.

Division of EndoResearch Inc.
www.endoceutics.com

Latest From Endoceutics Inc.

Proof Suggested For DHEA Improving Pre-Menopausal Women's Sex Drive

"We've identified the patient population that would benefit from this," said Vitaly Kushnir, of  the Center for Human Reproduction. Fertility Nutraceuticals-backed study shows subjects' Female Sexual Function Index scores increased by 17% for desire, 12% for arousal and 8% for lubrication.

Dietary Supplements Advertising, Marketing & Sales

Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics

Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.
Deals Business Strategies

EU CHMP OKs New Treatments For MS, Esophagitis, CMV, Hemophilia – & First Biosimilar Avastin

The EMA’s scientific committee, the CHMP, has given the green light to new treatments for multiple sclerosis, eosinophilic esophagitis, CMV, hemophilia A, and vaginal atrophy, as well as the EU’s first biosimilar version of Roche’s Avastin. The committee upheld two earlier negative opinions, and two products have been withdrawn from the assessment process.

Drug Review Approvals

CHMP OKs Drugs For MS, Esophagitis, CMV & Hemophilia – And First EU Biosimilar Avastin

At its November meeting, the CHMP finally OKd Roche's Ocrevus for multiple sclerosis and gave the green light to new drugs for eosinophilic esophagitis, CMV, hemophilia A, and vaginal atrophy, as well as Amgen’s Mvasi, the first EU biosimilar version of Roche’s Avastin. The committee upheld two earlier negative opinions, and two products were withdrawn from the assessment process.

Drug Review Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • EndoResearch Inc.
  • Senior Management
  • Fernand Labrie, MD, PhD, Pres.
    Karl McLellan, VP, Fin.
    Jaafar Zerhouni, VP, Quality Assurance & Product Dev.
  • Contact Info
  • Endoceutics Inc.
    Phone: (418) 653-0033
    2795 Laurier Blvd.
    Ste. 500
    Quebec, G1V 4M7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register